Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
May 06 2016 - 6:00AM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and Clostridium difficile infection (‘CDI’),
will be announcing its financial results for the fourth quarter and
fiscal year ended 31 January 2016 on Tuesday, 10 May 2015.
Summit will host a conference call the same day at 1:00pm BST /
8:00am EDT. Conference call information will be included in the
full year results press release and a replay of the call will also
be available through the Company’s website, www.summitplc.com.
About Summit TherapeuticsSummit is a
biopharmaceutical company focused on the discovery, development and
commercialization of novel medicines for indications for which
there are no existing or only inadequate therapies. Summit is
conducting clinical programs focused on the genetic disease
Duchenne muscular dystrophy and the infectious disease C. difficile
infection. Further information is available at
www.summitplc.com and Summit can be followed on Twitter
(@summitplc).
For more information, please
contact:
Summit
Therapeutics |
|
Glyn Edwards
/ Richard Pye (UK office) |
Tel: +44 (0)1235 443
951 |
Erik Ostrowski /
Michelle Avery (US office) |
+1 617 225 4455 |
|
|
Cairn Financial
Advisers LLP |
|
(Nominated
Adviser) |
|
Liam Murray / Tony
Rawlinson |
Tel: +44 (0)20 7148
7900 |
|
|
N+1
Singer |
|
(Broker) |
|
Aubrey Powell / Jen
Boorer |
Tel: +44 (0)20 7496
3000 |
|
|
MacDougall
Biomedical Communications
|
|
(US media contact) |
Tel: +1 781 235
3060 |
Chris Erdman / Karen
Sharma |
cerdman@macbiocom.com |
|
|
Consilium
Strategic Communications |
|
(Financial public
relations, UK) |
Tel: +44 (0)20 3709
5700 |
Mary-Jane Elliott / Sue
Stuart / |
summit@consilium-comms.com |
Jessica Hodgson /
Lindsey Neville |
|
- END -
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Sep 2023 to Sep 2024